A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population-Reference-Cited by-同舟云学术

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population

Published:2017-01 Issue: Volume:103 Page:82-89
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gow Chien-Hung,Hsieh Min-Shu,Wu Shang-Gin,Shih Jin-Yuan

Funder

Far Eastern Memorial Hospital–National Taiwan University Hospital Joint Research Program grant

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference38 articles.

1. Annual report to the nation on the status of cancer 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control;Jemal;J. Natl. Cancer Inst.,2008

2. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis;Shaw;Lancet Oncol.,2011

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

4. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J. Clin. Oncol.,2012

5. Ceritinib in ALK-rearranged non-small-cell lung cancer;Shaw;N. Engl. J. Med.,2014

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering immunohistochemistry in lung cancer;Critical Reviews in Oncology/Hematology;2024-08

2. Molecular Methods;Clinics in Laboratory Medicine;2024-06

3. Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment;Frontiers in Oncology;2024-04-19

4. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION;British Journal of Cancer;2024-04-04

5. Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study;Cancer Science;2024-02-25